Serum Presepsin as Early Predictor for Neonatal Early-onset Sepsis

Tanta University

Status

Completed

Conditions

Neonatal Sepsis

Treatments

Diagnostic Test: Serum Presepsin

Study type

Interventional

Funder types

Other

Identifiers

NCT05022043

34817/7/21

Details and patient eligibility

About

124 neonates aged ≤7 days with suspected EOS were clinically evaluated using SNAP-II and gave blood samples for BC, total leucocytic count (TLC), lymphocytic and neutrophil count, and ELISA estimation of serum levels of PSP, procalcitonin (PCT), and tumor necrosis factor-α (TNF-α). Enrolled neonates were categorized as Confirmed EOS: neonates with evident clinical sepsis manifestations and positive BC, Suspected EOS: neonates with evident clinical sepsis manifestations but had negative BC and No EOS included neonates free of evident clinical sepsis manifestations, had negative BC and showed no deterioration till 72-hr after admission.

Enrollment

124 patients

Sex

All

Ages

1 to 7 days old

Volunteers

No Healthy Volunteers

Inclusion criteria

included gestational age (GA) of 28-41 weeks and 5-min APGAR score of ≥7, and neonatal age of <7 days

Exclusion criteria

including small for gestational age, presence of a chromosomal abnormality, multiple congenital anomalies, genetic syndromes, history of premature rupture of membranes, chorioamnionitis, neonatal asphyxia, and missed inclusion criterion.